Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

516
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
516
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

295
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
295
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

358
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
358
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

430
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
430
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

647
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
647
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

433
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
433

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Autophagy in thyroid cancer: Immune suppression and drug resistance.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2026
Same author

A Age Related Vascular Senescence: Mystery of Blood-brain Barrier Dysfunction in Neurodegeneration.

Molecular neurobiology·2026
Same author

Neurovascular Uncoupling in Alzheimer's and Parkinson's Diseases: Mechanisms and Therapeutic Strategies.

Brain sciences·2026
Same author

Neuroprotective role of cyanidin in Alzheimer's and Parkinson's disease: current insights and the road ahead.

Inflammopharmacology·2026
Same author

Neuroimmune Interactions in Neurodegeneration: The Role of Microglia in Alzheimer's and Parkinson's Disease Pathogenesis.

Brain sciences·2026
Same author

Advocating gut-retina connection and microbiota mediated pathways in management of age-related macular degeneration: Preclinical to clinical perspective.

Ageing research reviews·2026

Video Experimental Relacionado

Updated: Jan 7, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K

Manifestaciones Clínicas

Bushra Bashir1, Sachin Kumar Singh1, Monica Gulati1

  • 1School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar, Punjab, India.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Este estudio demuestra que la combinación de Xantohumol (XH) y Quercetina (Qu) mejoró eficazmente la función cognitiva en ratas con Alzheimer.

Palabras clave:
XantohumolQuercetinaEnfermedad de AlzheimerTerapia combinadaFunción cognitivaNeuroprotecciónEstrés oxidativo

Más Videos Relacionados

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.1K

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.1K

Área de la Ciencia:

  • Neurociencia
  • Farmacología

Sus antecedentes:

  • La enfermedad de Alzheimer (EA) es un trastorno neurodegenerativo con opciones de tratamiento limitadas.
  • Las características patológicas incluyen ovillos neurofibrilares y placas de beta amiloide.
  • El Xantohumol (XH) y la Quercetina (Qu) muestran potenciales efectos neuroprotectores.

Objetivo del estudio:

  • Investigar el potencial terapéutico de la combinación de XH y Qu para la enfermedad de Alzheimer.
  • Evaluar los efectos neuroprotectores y antiinflamatorios de XH y Qu.
  • Determinar la dosis óptima para el tratamiento combinado de XH y Qu.

Principales métodos:

  • Estudios farmacodinámicos utilizando la prueba de Morris water maze en ratas.
  • Evaluaciones bioquímicas de marcadores de la enfermedad de Alzheimer (AChE, Aβ).
  • Medición de marcadores de estrés oxidativo y neuroinflamación.

Principales resultados:

  • La combinación de XH y Qu mejoró significativamente la función cognitiva en ratas.
  • El tratamiento redujo la actividad de la acetilcolinesterasa y los niveles de amiloide beta.
  • La terapia combinada mitigó eficazmente el estrés oxidativo y la neuroinflamación.

Conclusiones:

  • La combinación de XH y Qu presenta una estrategia terapéutica prometedora para el manejo de la enfermedad de Alzheimer.
  • Este enfoque sinérgico ofrece beneficios neuroprotectores contra la progresión de la EA.
  • Se justifica una mayor investigación sobre XH y Qu como terapéuticos para la EA.